KNTPF (Kintor Pharmaceutical) Research & Development: $12.28 Mil (TTM As of Dec. 2025)


KNTPF Kintor Pharmaceutical Ltd KNTPF
20 GF Score
Price $0.34
! 3 Warning Signs
View Full Analysis

What is Kintor Pharmaceutical Research & Development?

Kintor Pharmaceutical KNTPF 20 Research & Development is $12.28 Mil as of Dec. 2025. GuruFocus rates KNTPF with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Kintor Pharmaceutical's Research & Development for the six months ended in Dec. 2025 was $5.50 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $12.28 Mil.

Kintor Pharmaceutical  (OTCPK:KNTPF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Kintor Pharmaceutical Research & Development Related Terms

Kintor Pharmaceutical Research & Development Historical Data

* Premium members only.

The historical data trend for Kintor Pharmaceutical's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kintor Pharmaceutical Research & Development Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 120.57 118.76 131.50 10.73 12.41

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.44 5.42 5.33 6.77 5.50
KNTPF
20GF Score
Kintor Pharmaceutical Ltd KNTPF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kintor Pharmaceutical Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $12.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $12.28 Mil mean?
Kintor Pharmaceutical (KNTPF) has a Research & Development of $12.28 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Kintor Pharmaceutical and its competitors.
Is Kintor Pharmaceutical's Research & Development too high?
Kintor Pharmaceutical's current Research & Development is $12.28 Mil. Overall, Kintor Pharmaceutical has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Research & Development compare to VRTX and REGN?
Kintor Pharmaceutical's Research & Development of $12.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Kintor Pharmaceutical and its competitors. Kintor Pharmaceutical's current Research & Development is $12.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Research & Development of $12.28 Mil. The current Research & Development is $12.28 Mil. Kintor Pharmaceutical's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Research & Development is $12.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kintor Pharmaceutical Business Description

Other Exchanges 09939:Hong Kong
Address No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
20GF Score

Get the complete analysis for KNTPF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price